Concurrent Investment Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.6M Buy
32,489
+1,159
+4% +$95.6K 0.03% 534
2025
Q4
$2.67M Buy
31,330
+1,135
+4% +$93.1K 0.03% 485
2025
Q3
$2.35M Sell
30,195
-195
-0.6% -$15.2K 0.04% 423
2025
Q2
$2.38M Buy
30,390
+3,481
+13% +$260K 0.05% 389
2025
Q1
$1.95M Buy
26,909
+7,283
+37% +$521K 0.05% 371
2024
Q4
$1.45M Buy
19,626
+439
+2% +$30.7K 0.04% 399
2024
Q3
$1.27M Buy
19,187
+636
+3% +$46.2K 0.04% 417
2024
Q2
$1.71M Sell
18,551
-126
-0.7% -$11.2K 0.06% 311
2024
Q1
$1.78M Sell
18,677
-4,003
-18% -$336K 0.07% 263
2023
Q4
$1.73M Buy
+22,680
New +$1.58M 0.08% 254

Other funds holding EW

Concurrent Investment Advisors's EW Position: Q1 2026 in Review

Concurrent Investment Advisors increased its Edwards Lifesciences (EW) stake by 3.7% in Q1 2026, buying an estimated $95.6K and bringing the position to 32,489 shares worth $2.6M. The position accounts for 0.03% of the portfolio, ranked #534.

Concurrent Investment Advisors first reported a position in EW in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.67M in Q4 2025. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Concurrent Investment Advisors held 32,489 shares of Edwards Lifesciences worth $2.6M as of Q1 2026.
  • Concurrent Investment Advisors bought 1,159 Edwards Lifesciences shares in Q1 2026, an estimated $95.6K.
  • Edwards Lifesciences made up 0.03% of Concurrent Investment Advisors's portfolio in Q1 2026, its #534 holding.
  • Concurrent Investment Advisors first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 10 quarters since.
  • Concurrent Investment Advisors's Edwards Lifesciences position peaked at $2.67M in Q4 2025.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Concurrent Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.